Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology

Neuropsychopharmacology

Volumn 37, Issue 4, 2012, Pages 1013-1025

  Ditzen, Claudia ^a   Tang, Ning ^b   Jastorff, Archana M ^a   Teplytska, Larysa ^a   Yassouridis, Alexander ^a   MacCarrone, Giuseppina ^a   Uhr, Manfred ^a   Bronisch, Thomas ^a   Miller, Christine A ^b   Holsboer, Florian ^a   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

cerebrospinal fluid biomarkers; cystatin C; major depression; PEDF; PGDS; phosphoproteins

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANGIOTENSINOGEN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN D; APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CLUSTERIN; COMPLEMENT COMPONENT C3; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; CYSTATIN C; EPIDIDYMAL SECRETORY PROTEIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GELSOLIN; GLUTAMATE CARBOXYPEPTIDASE II; HEAT SHOCK PROTEIN; HEMOPEXIN; HERMES ANTIGEN; OROSOMUCOID; PIGMENT EPITHELIUM DERIVED FACTOR; PREALBUMIN; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROTEOME; PROTHROMBIN; RIBONUCLEOPROTEIN; UNINDEXED DRUG; VITAMIN D BINDING PROTEIN;

ADULT; AGING; AMINO ACID SEQUENCE; AMYLOID PLAQUE; ARTICLE; BRAIN; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOBLOTTING; MAJOR DEPRESSION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MENTAL PATIENT; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SLEEP; TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ADULT; AGED; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS;

EID: 84857037858     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.285     Document Type: Article

References (44)

1. aan het Rot M, Mathew SJ, Charney DS (2009). Neurobiological mechanisms in major depressive disorder. CMAJ 180: 305-313.
2. Brummer D, Evans D, Berg D, Greten H, Beisiegel U, Mann WA (1998). Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia. J Mol Med 76: 355-364. (Pubitemid 28168334)
3. Brunner J, Bronisch T, Uhr M, Ising M, Binder E, Holsboer F et al (2005). Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters. Eur Arch Psychiatry Clin Neurosci 255: 438-440. (Pubitemid 43029833)
4. Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ et al (2008). Depressive symptoms and metabolic syndrome: Is inflammation the underlying link? Biol Psychiatry 64: 896-900.
5. Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH (2004). Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord 79: 285-289. (Pubitemid 38340558)
6. Eguchi N, Minami T, Shirafuji N, Kanaoka Y, Tanaka T, Nagata A et al (1999). Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc Natl Acad Sci USA 96: 726-730. (Pubitemid 29061276)
7. Geracioti TD, Loosen PT, Orth DN (1997). Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 42: 165-174.
8. Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G (2010). Neural cell adhesion molecule-description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. J Neuroimmunol 225: 118-122.
9. Henneman WJ, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA et al (2009). Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73: 935-940.
10. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S et al (2009). Clinical characteristics and treatment outcome in a representative sample of depressed inpatients -findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43: 215-229.
11. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S et al (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66: 966-975.
12. Jacob AM, Turck CW (2008). Detection of post-translational modifications by fluorescent staining of two-dimensional gels. Methods Mol Biol 446: 21-32.
13. Jakovljevic M, Crncevic Z, Ljubicic D, Babic D, Topic R, Saric M (2007). Mental disorders and metabolic syndrome: A fatamorgana or warning reality? Psychiatr Danub 19: 76-86. (Pubitemid 47045674)
14. Jastorff AM, Haegler K, Maccarrone G, Holsboer F, Weber F, Ziemssen T et al (2009). Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Proteomics Clin Appl 3: 1273-1287.
15. Jokinen J, Samuelsson M, Nordstrom AL, Nordstrom P (2008). HPT axis, CSF monoamine metabolites, suicide intent and depression severity in male suicide attempters. J Affect Disord 111: 119-124.
16. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT et al (2007). Cystatin C modulates cerebral betaamyloidosis. Nat Genet 39: 1437-1439.
17. Krishnan V, Nestler EJ (2010). Linking Molecules to Mood: New Insight into the biology of depression. Am J Psychiatry 167: 1305-1320.
18. Lee S, Jeong J, Kwak Y, Park SK (2010). Depression research: Where are we now? Mol Brain 3: 8.
19. Levy E, Jaskolski M, Grubb A (2006). The role of cystatin C in cerebral amyloid angiopathy and stroke: Cell biology and animal models. Brain Pathol 16: 60-70.
20. Lottspeich F, Kellermann J, Keidel EM (2010). Molecular biology tools: Proteomics techniques in biomarker discovery. Scand J Clin Lab Invest Suppl 242: 19-22.
21. Luo L, Rodriguez E, Jerbi K, Lachaux JP, Martinerie J, Corbetta M et al (2010). Ten years of Nature Reviews Neuroscience: Insights from the highly cited. Nat Rev Neurosci 11: 718-726.
22. Maccarrone G, Milfay D, Birg I, Rosenhagen M, Holsboer F, Grimm R et al (2004). Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis 25: 2402-2412. (Pubitemid 39136361)
23. Matsumura H, Nakajima T, Osaka T, Satoh S, Kawase K, Kubo E et al (1994). Prostaglandin D2-sensitive, sleep-promoting zone defined in the ventral surface of the rostral basal forebrain. Proc Natl Acad Sci USA 91: 11998-12002. (Pubitemid 24368591)
24. Petzold A, Thompson EJ, Keir G, Quinn N, Holmberg B, Dizdar N et al (2009). Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. J Neurol Sci 279: 76-79.
25. Pijnenburg YA, Janssen JC, Schoonenboom NS, Petzold A, Mulder C, Stigbrand T et al (2007). CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer0s disease and controls. Dement Geriatr Cogn Disord 23: 225-230. (Pubitemid 46496808)
26. Poltorak M, Frye MA, Wright R, Hemperley JJ, George MS, Pazzaglia PJ et al (1996). Increased neural cell adhesion molecule in the CSF of patients with mood disorder. J Neurochem 66: 1532-1538. (Pubitemid 26090556)
27. Popoli M, Brunello N, Perez J, Racagni G (2000). Second messengerregulated protein kinases in the brain: Their functional role and the action of antidepressant drugs. J Neurochem 74: 21-33. (Pubitemid 30012751)
28. Richter N, Juckel G, Assion HJ (2010). Metabolic syndrome: A follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci 260: 41-49.
29. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 163: 1905-1917. (Pubitemid 44807782)
30. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Peterson RC et al (2009). Cerebrospinal fluid biomarker signature in Alzheimer0s disease neuroimaging initiative subjects. Ann Neurol 65: 403-413.
31. Sri Kantha S, Matsumura H, Kubo E, Kawase K, Takahata R, Serhan CN et al (1994). Effects of prostaglandin D2, lipoxins and leukotrienes on sleep and brain temperature of rats. Prostaglandins Leukot Essent Fatty Acids 51: 87-93.
32. Sullivan GM, Oquendo MA, Huang YY, Mann JJ (2006). Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid levels in women with comorbid depression and panic disorder. Int J Neuropsychopharmacol 9: 547-556. (Pubitemid 44607207)
33. Taurines R, Dudley E, Grassl J, Warnke A, Gerlach M, Coogan AN et al (2011). Proteomic research in psychiatry. J Psychopharmacol 25: 151-196.
34. Tombran-Tink J, Barnstable CJ (2003). PEDF: A multifaceted neurotrophic factor. Nat Rev Neurosci 4: 628-636. (Pubitemid 37280158)
35. Turck CW, Maccarrone G, Sayan-Ayata E, Jacob AM, Ditzen C, Kronsbein H et al (2005). The quest for brain disorder biomarkers. J Med Invest 52(Suppl): 231-235.
36. Urade Y, Hayaishi O (1999). Prostaglandin D2 and sleep regulation. Biochim Biophys Acta 1436: 606-615.
37. Vawter MP (2000). Dysregulation of the neural cell adhesion molecule and neuropsychiatric disorders. Eur J Pharmacol 405: 385-395.
38. Vawter MP, Frye MA, Hemperly JJ, VanderPutten DM, Usen N, Doherty P et al (2000). Elevated concentration of N-CAM VASE isoforms in schizophrenia. J Psychiatr Res 34: 25-34. (Pubitemid 30006938)
39. Vogelzangs N, Suthers K, Ferrucci L, Simonsick EM, Ble A, Schrager M et al (2007). Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 32: 151-159. (Pubitemid 46274017)
40. Yabe T, Kanemitsu K, Sanagi T, Schwartz JP, Yamada H (2005). Pigment epithelium-derived factor induces pro-survival genes through cyclic AMP-responsive element binding protein and nuclear factor kappa B activation in rat cultured cerebellar granule cells: Implication for its neuroprotective effect. Neuroscience 133: 691-700. (Pubitemid 40798322)
41. Yamada S, Yamamoto M, Ozawa H, Riederer P, Saito T (2003). Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm 110: 671-680. (Pubitemid 36683520)
42. Yamashima T, Sakuda K, Tohma Y, Yamashita J, Oda H, Irikura D et al (1997). Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: Roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process. J Neurosci 17: 2376-2382. (Pubitemid 27137404)
43. Yuan X, Russell T, Wood G, Desiderio DM (2002). Analysis of the human lumbar cerebrospinal fluid proteome. Electrophoresis 23: 1185-1196.
44. Zougman A, Pilch B, Podtelejnikov A, Kiehntof M, Schnabel C, Kumar C et al (2008). Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 7: 386-399. (Pubitemid 351171153)